135 related articles for article (PubMed ID: 3671911)
41. Voided urinary cytology in bladder cancer: is it time to review the indications?
Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
[TBL] [Abstract][Full Text] [Related]
42. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
43. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
44. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
45. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
46. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
47. Flow cytometry based on heterogeneity index score compared with urine cytology to evaluate their diagnostic efficacy in bladder tumor.
Jitsukawa S; Tachibana M; Nakazono M; Tazaki H; Addonizio JC
Urology; 1987 Feb; 29(2):218-22. PubMed ID: 3811103
[TBL] [Abstract][Full Text] [Related]
48. Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: critical review of a 5-year experience.
Billerey C; Lamy B; Bittard H; Rozan S; Carbillet JP
World J Urol; 1993; 11(3):156-60. PubMed ID: 8401634
[TBL] [Abstract][Full Text] [Related]
49. DNA tetraploidy in Feulgen-stained bladder washings assessed by image cytometry.
Kline MJ; Wilkinson EJ; Askeland R; Given RW; Stephen C; Hendricks JB
Anal Quant Cytol Histol; 1995 Apr; 17(2):129-34. PubMed ID: 7542000
[TBL] [Abstract][Full Text] [Related]
50. Flow cytometric analysis of deparaffinized nuclei in urinary bladder carcinoma. Comparison with cytogenetic analysis.
Coon JS; Schwartz D; Summers JL; Miller AW; Weinstein RS
Cancer; 1986 Apr; 57(8):1594-601. PubMed ID: 3948130
[TBL] [Abstract][Full Text] [Related]
51. Multidimensional slit-scan detection of bladder cancer. Preliminary clinical results.
Wheeless LL; Berkan TK; Patten SF; Reeder JE; Robinson RD; Eldidi MM; Hulbert WC; Frank IN
Cytometry; 1986 Mar; 7(2):212-6. PubMed ID: 2419061
[TBL] [Abstract][Full Text] [Related]
52. Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases.
Bakhos R; Shankey TV; Flanigan RC; Fisher S; Wojcik EM
Diagn Cytopathol; 2000 Feb; 22(2):65-9. PubMed ID: 10649514
[TBL] [Abstract][Full Text] [Related]
53. Bladder transitional cell carcinomas: a comparative study of washing and tumor bioptic samples by DNA flow cytometry and FISH analyses.
Eleuteri P; Grollino MG; Pomponi D; Guaglianone S; Gallucci M; De Vita R
Eur Urol; 2000 Mar; 37(3):275-80. PubMed ID: 10720852
[TBL] [Abstract][Full Text] [Related]
54. Significance of flow cytometry in the diagnosis and treatment of bladder tumors.
Song Z; Sun X; Wu D
Chin Med Sci J; 1995 Mar; 10(1):38-41. PubMed ID: 7780116
[TBL] [Abstract][Full Text] [Related]
55. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer.
Murphy WM; Emerson LD; Chandler RW; Moinuddin SM; Soloway MS
J Urol; 1986 Oct; 136(4):815-9. PubMed ID: 3761437
[TBL] [Abstract][Full Text] [Related]
56. Bladder cancer diagnosis by flow cytometry. Correlation between cell samples from biopsy and bladder irrigation fluid.
Collste LG; Devonec M; Darzynkiewicz Z; Traganos F; Sharpless TK; Whitmore WF; Melamed MR
Cancer; 1980 May; 45(9):2389-94. PubMed ID: 6155204
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometric analysis of DNA content in human bladder tumors and irrigation fluids.
Chin JL; Huben RP; Nava E; Rustum YM; Greco JM; Pontes JE; Frankfurt OS
Cancer; 1985 Oct; 56(7):1677-81. PubMed ID: 4027899
[TBL] [Abstract][Full Text] [Related]
58. Bladder wash cytology and flow cytometry for the diagnosis of transitional cell carcinoma of the urinary bladder.
Romero J; Alos L; Mallofre C; Sole M; Gutierrez R; Alcover J; Carretero P
Eur Urol; 1992; 21 Suppl 1():13-5. PubMed ID: 1425832
[TBL] [Abstract][Full Text] [Related]
59. Intratumoral heterogeneity of DNA indexes in transitional cell bladder cancer: relation to tumor histology.
Lipponen PK; Eskelinen MJ; Nordling S
Eur Urol; 1991; 20(4):311-4. PubMed ID: 1814748
[TBL] [Abstract][Full Text] [Related]
60. Flow cytometry for detection and evaluation of urinary bladder carcinoma.
Melamed MR
Semin Surg Oncol; 1992; 8(5):300-7. PubMed ID: 1462101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
